1. Home
  2. RSG vs ARGX Comparison

RSG vs ARGX Comparison

Compare RSG & ARGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Republic Services Inc.

RSG

Republic Services Inc.

SELL

Current Price

$254.91

Market Cap

67.1B

Sector

Utilities

ML Signal

SELL

Logo argenx SE

ARGX

argenx SE

SELL

Current Price

$936.48

Market Cap

55.1B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
RSG
ARGX
Founded
1996
2008
Country
United States
Netherlands
Employees
N/A
N/A
Industry
Environmental Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
67.1B
55.1B
IPO Year
1998
2017

Fundamental Metrics

Financial Performance
Metric
RSG
ARGX
Price
$254.91
$936.48
Analyst Decision
Buy
Buy
Analyst Count
27
25
Target Price
$257.42
★ $1,150.61
AVG Volume (30 Days)
★ 1.3M
377.9K
Earning Date
10-29-2026
10-22-2026
Dividend Yield
★ 1.05%
N/A
EPS Growth
★ 5.55
N/A
EPS
★ 5.47
N/A
Revenue
★ $19,027,000,000.00
N/A
Revenue This Year
$5.33
$53.06
Revenue Next Year
$4.99
$23.03
P/E Ratio
$46.73
★ $33.69
Revenue Growth
★ 3.31
N/A
52 Week Low
$196.41
$661.85
52 Week High
$256.79
$1,072.75

Technical Indicators

Market Signals
Indicator
RSG
ARGX
Relative Strength Index (RSI) 71.62 54.20
Support Level $206.53 $934.19
Resistance Level N/A $1,072.75
Average True Range (ATR) 4.70 25.28
MACD 0.40 6.39
Stochastic Oscillator 91.65 59.40

Price Performance

Historical Comparison
RSG
ARGX

About RSG Republic Services Inc.

Republic Services Group is the second-largest waste management company by revenue and provides integrated waste management services to residential, commercial, and industrial customers. With 208 active landfills, 248 transfer stations, and 75 recycling centers, Republic Services has reached $16 billion in annual revenue, focusing on recycling and environmental solutions. The company reports in three segments based on the Western United States (Group 1), Eastern United States (Group 2), and Environmental Solutions across North America (Group 3). Eighty-nine percent of total revenue comes from recycling and waste, with the remaining 11% from Environmental Solutions.

About ARGX argenx SE

Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.

Share on Social Networks: